Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Telecon with Fresenius Kabi - 12/14/2007 - Voluven

Telecon with Fresenius Kabi

RE: BN070012

Meeting called by:Franklin. Stephenson/ RPM

Type of meeting: Telecon 919-881-9900

FDA Participants: Franklin Stephenson, Dr. Lawrence Landow, Pauline Cottrell

Baxter Participants: Mr. Coln


Conversation Record:

We contacted Mr. Coln and indicated to him that the PREA Advisory committee has conviened and the following suggestions have been placed forward:

  • For Fresenius Kabi to commit to perform a Safety Study in 2- 12 year old population similar to a sepsis trial. FDA would need to see a description of the methods, population, overview, and an agreement to due diligence. Fresenius Kabi must follow the schedule as agreed.
  • The language for the pediatric section needs to be strenghtened to indicate that the 2- 12 age range population has not been studied therefore, they cannot recommend a dose as of yet.

Mr. Coln told us that we would bring the issue to F. Kabi and would get back to us by Monday Dec. 17, 2007.

Franklin T. Stephenson, Pauline Cottrell
Regulatory Project Manager

Page Last Updated: 02/21/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English